430 related articles for article (PubMed ID: 23575971)
1. Synthesis and evaluation of 3-amino/guanidine substituted phenyl oxazoles as a novel class of LSD1 inhibitors with anti-proliferative properties.
Dulla B; Kirla KT; Rathore V; Deora GS; Kavela S; Maddika S; Chatti K; Reiser O; Iqbal J; Pal M
Org Biomol Chem; 2013 May; 11(19):3103-7. PubMed ID: 23575971
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents.
Ma LY; Zheng YC; Wang SQ; Wang B; Wang ZR; Pang LP; Zhang M; Wang JW; Ding L; Li J; Wang C; Hu B; Liu Y; Zhang XD; Wang JJ; Wang ZJ; Zhao W; Liu HM
J Med Chem; 2015 Feb; 58(4):1705-16. PubMed ID: 25610955
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X
Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
[TBL] [Abstract][Full Text] [Related]
5. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
Zhang X; Huang H; Zhang Z; Yan J; Wu T; Yin W; Sun Y; Wang X; Gu Y; Zhao D; Cheng M
Eur J Med Chem; 2021 Aug; 220():113501. PubMed ID: 33945992
[TBL] [Abstract][Full Text] [Related]
9. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
[TBL] [Abstract][Full Text] [Related]
10. Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing.
Li Z; Qin T; Li Z; Zhao X; Zhang X; Zhao T; Yang N; Miao J; Ma J; Zhang Z
Eur J Med Chem; 2021 Dec; 225():113778. PubMed ID: 34416665
[TBL] [Abstract][Full Text] [Related]
11. Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration.
Zheng YC; Duan YC; Ma JL; Xu RM; Zi X; Lv WL; Wang MM; Ye XW; Zhu S; Mobley D; Zhu YY; Wang JW; Li JF; Wang ZR; Zhao W; Liu HM
J Med Chem; 2013 Nov; 56(21):8543-60. PubMed ID: 24131029
[TBL] [Abstract][Full Text] [Related]
12. Exploring cyclopropylamine containing cyanopyrimidines as LSD1 inhibitors: Design, synthesis, ADMET, MD analysis and anticancer activity profiling.
Ahmad Sheikh K; Parveen D; Mumtaz Alam M; Azam F; Ahmed Khan M; Akhter M; Tasneem S; Meenu ; Parvez S; Imtiyaz K; Rizvi MA; Shaquiquzzaman M
Bioorg Chem; 2024 Jun; 147():107336. PubMed ID: 38636431
[TBL] [Abstract][Full Text] [Related]
13. Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors.
Benelkebir H; Hodgkinson C; Duriez PJ; Hayden AL; Bulleid RA; Crabb SJ; Packham G; Ganesan A
Bioorg Med Chem; 2011 Jun; 19(12):3709-16. PubMed ID: 21382717
[TBL] [Abstract][Full Text] [Related]
14. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
Rotili D; Tomassi S; Conte M; Benedetti R; Tortorici M; Ciossani G; Valente S; Marrocco B; Labella D; Novellino E; Mattevi A; Altucci L; Tumber A; Yapp C; King ON; Hopkinson RJ; Kawamura A; Schofield CJ; Mai A
J Med Chem; 2014 Jan; 57(1):42-55. PubMed ID: 24325601
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.
Chen CL; Chang DM; Chen TC; Lee CC; Hsieh HH; Huang FC; Huang KF; Guh JH; Lin JJ; Huang HS
Eur J Med Chem; 2013 Feb; 60():29-41. PubMed ID: 23279865
[TBL] [Abstract][Full Text] [Related]
16. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of heterocyclic azoles derivatives containing pyrazine moiety as potential telomerase inhibitors.
Zhang YB; Wang XL; Liu W; Yang YS; Tang JF; Zhu HL
Bioorg Med Chem; 2012 Nov; 20(21):6356-65. PubMed ID: 23018096
[TBL] [Abstract][Full Text] [Related]
19. Syntheses of amamistatin fragments and determination of their HDAC and antitumor activity.
Fennell KA; Miller MJ
Org Lett; 2007 Apr; 9(9):1683-5. PubMed ID: 17397173
[TBL] [Abstract][Full Text] [Related]
20. Identification of fenoldopam as a novel LSD1 inhibitor to abrogate the proliferation of renal cell carcinoma using drug repurposing strategy.
Zheng Y; Ma Y; Cao H; Yan L; Gu Y; Ren X; Jiao X; Wan S; Shao F
Bioorg Chem; 2021 Mar; 108():104561. PubMed ID: 33349457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
